Avolta is proud to announce it has acted as exclusive advisor to LatticeMedical, a pioneering French MedTech company specializing in regenerative soft-tissue reconstruction, on its €43 million Series B funding round, one of the largest Medtech deals of the year in France.
This landmark transaction was led by Bpifrance SPI, followed by Blast.club, Sprim, and industry specialists via TIDJEE, alongside historical investors EIC Fund, Captech Santé, Nord France Amorçage, and FIRA Nord Est.
The round was completed with non-dilutive funding from banking partners and the France 2030 programs M3DINPRINT and LIPOTEC.
About Lattice Medical.
Founded in Lille, France, Lattice Medical is an implantable medical device company developing disruptive technology in the field of autologous soft tissue reconstruction using 3D printing technology.
Its mission is to reinvent medical solutions for tissue regeneration and to improve patients’ quality of life after cancer.
The company is currently developing two flagship products:
- MATTISSE, a resorbable implant for autologous breast reconstruction after breast cancer (in clinical trials)
- RODIN, a matrix for the reconstruction of large subcutaneous tissue defects
Transaction rationale.
This Series B round marks a major milestone in Lattice Medical’s growth, enabling the company to accelerate clinical development through to regulatory approval, scale its manufacturing capabilities, and prepare for international commercialization of its breakthrough technologies.
About Avolta.
Advising Lattice Medical in this landmark Series B further strengthens Avolta’s Medtech track record following its advisory role with Posos and confirms Avolta’s leading position in the DeepTech hardware sector, following recent transactions such as Space Cargo Unlimited, TiHive, Aisprid, and Hexana.
This deal reflects Avolta’s commitment to supporting visionary founders at the intersection of science, technology, and impact.
